The Joint Commission Accredited
The Gold Seal of Approval® recognizes Green Springs Wellness’s adherence to rigorous national standards for healthcare quality, patient safety and continuous performance improvement.
Ketamine-based treatments have become increasingly visible in mental health care.
People struggling with depression may hear about Spravato, ketamine infusions, ketamine-assisted therapy, compounded ketamine lozenges, or online programs offering ketamine products for use at home.
For someone who has not improved with traditional treatment, the possibility of a faster-acting option can sound promising.
But there is an important distinction that is often lost in online discussions:
Spravato, medically supervised ketamine, compounded ketamine, and recreational ketamine are not interchangeable.
That distinction becomes particularly important when depression, trauma, anxiety, chronic pain, and substance use overlap.
Green Springs Wellness in Hillsborough, New Jersey provides structured treatment for depression, addiction, trauma, and co-occurring mental health concerns through partial hospitalization, intensive outpatient treatment, outpatient care, and evidence-based therapies.
Interest in ketamine treatment has grown quickly, but so have concerns about how ketamine products are marketed and obtained.
On June 23, 2026, the U.S. Food and Drug Administration issued multiple warning letters involving websites selling unapproved ketamine products, including products marketed for psychiatric conditions.
The FDA specifically distinguishes ketamine from Spravato.
Ketamine is FDA-approved as an anesthetic and is not FDA-approved for treating psychiatric disorders. Spravato contains esketamine, a ketamine derivative, and has specific FDA-approved indications for depression.
That distinction matters because an advertisement for "ketamine therapy" does not tell someone whether the product is FDA-approved, being used off-label, compounded, or being sold through an unsafe source.
Ketamine is a dissociative anesthetic that has been used medically for decades.
It affects several systems in the brain, including glutamate activity involving NMDA receptors. These effects can influence pain perception, mood, memory, awareness, and how connected a person feels to their body and surroundings.
Ketamine is FDA-approved as an anesthetic.
Ketamine itself is not FDA-approved specifically for psychiatric disorders, although clinicians may use it off-label when they determine that doing so is medically appropriate.
Off-label prescribing can be a legitimate part of medical practice. It simply means the specific use has not received FDA approval for that medication.
Patients considering ketamine for depression should understand exactly what medication they are receiving, why it is being recommended, how treatment is monitored, and what alternatives are available.
Spravato is the brand name for esketamine nasal spray.
Esketamine is chemically related to ketamine, but Spravato is not simply ordinary ketamine placed into a nasal spray.
Current FDA labeling includes Spravato for treatment-resistant depression in adults as monotherapy or together with an oral antidepressant. It is also approved, together with an oral antidepressant, for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior.
Spravato is administered through a restricted Risk Evaluation and Mitigation Strategy, or REMS.
Patients receive the medication in a certified healthcare setting and are monitored for at least two hours after administration.
Spravato’s boxed warning addresses significant risks involving:
Spravato can also temporarily increase blood pressure.
These warnings do not mean that Spravato is an inappropriate treatment.
They mean the FDA recognizes both a legitimate clinical role and risks significant enough to require controlled administration and monitoring.
A person appropriately receiving Spravato should not be treated as though they are engaging in recreational drug use.
At the same time, a history of substance misuse is relevant when evaluating a psychoactive medication with recognized abuse potential.
| Treatment | What It Is | Important Consideration |
|---|---|---|
| Spravato | FDA-approved esketamine nasal spray | Used for specific depression indications and administered in certified healthcare settings under REMS requirements |
| Ketamine Infusion | Ketamine administered clinically, often intravenously | Psychiatric use of ketamine itself is generally off-label |
| Compounded Ketamine | Ketamine prepared in forms such as troches, lozenges, or nasal products | Compounded drugs do not undergo the same FDA premarket review as approved medications |
| Recreational Ketamine | Nonmedical ketamine use for intoxication or dissociation | May involve escalating doses, polysubstance exposure, accidents, dependence, and serious physical complications |
Understanding which treatment someone is actually receiving is more useful than treating every ketamine-related product as equivalent.
Ketamine-related treatment has attracted attention partly because of the possibility of relatively rapid changes in depressive symptoms.
Traditional antidepressants can take time to produce noticeable improvement, and some people continue experiencing significant depression despite previous treatments.
Spravato provides another treatment option for appropriately selected adults with treatment-resistant depression.
However, symptom relief from medication is not always the same as broader emotional recovery.
Depression can affect motivation, sleep, relationships, work, school, concentration, self-worth, daily routines, and substance use.
Green Springs Wellness provides depression treatment in New Jersey for people who need more support than weekly therapy alone or who are also experiencing substance-use concerns.
Some people begin drinking or using drugs to cope with hopelessness, numbness, trauma, loneliness, or chronic stress.
Substances may provide temporary relief.
Over time, however, they can worsen sleep, relationships, motivation, mood stability, physical health, and everyday functioning.
The worsening depression can then increase the desire to use substances again.
When both problems are present, treatment needs to ask more than, "How do we stop the drug?"
It also needs to ask:
What is driving the person’s need to escape, numb, or disconnect?
Green Springs Wellness treats addiction and co-occurring mental health concerns together through its broader addiction and behavioral health programs.
Ketamine has recognized abuse and dependence potential.
That does not mean everyone receiving supervised ketamine treatment or Spravato will develop addiction.
Concern increases when the pattern of use begins changing.
Warning signs can include:
The issue is not simply whether someone has ever received ketamine.
The more important question is whether use remains within a carefully monitored treatment plan or is becoming difficult to control.
Growing medical use of ketamine has occurred alongside continued recreational misuse.
A 2026 systematic review in the Journal of Substance Use and Addiction Treatment described chronic ketamine misuse as being associated with dependence, ulcerative cystitis, gastrointestinal problems, cognitive changes, affective symptoms, and psychotic disturbances.
The review also found that evidence for treating ketamine misuse remains fragmented.
That is important because it means there is not one simple medication or standardized protocol that resolves every case of problematic ketamine use.
Treatment may need to address substance-use patterns, depression, trauma, anxiety, social circumstances, and physical complications together.
Ketamine can create a feeling of separation from the body, surroundings, thoughts, or emotions.
For someone living with severe depression, trauma, anxiety, or chronic pain, that temporary distance may feel relieving.
But repeatedly disconnecting from emotional pain is different from learning how to manage it.
A pattern may develop:
Emotional distress becomes intense.
Ketamine creates temporary distance from the distress.
The effects wear off.
The original distress remains.
The person increasingly wants the dissociative experience again.
For people with substance-use histories, this possibility is worth discussing openly with the clinician overseeing treatment.
Trauma can influence both mental health symptoms and substance-use patterns.
Someone experiencing trauma may struggle with intrusive memories, hypervigilance, emotional numbness, anxiety, avoidance, or persistent feelings of danger.
A dissociative drug may feel appealing precisely because it changes awareness for a period of time.
But avoiding traumatic emotions and processing trauma are not the same thing.
Green Springs Wellness provides trauma therapy in New Jersey using individualized, trauma-informed treatment that may incorporate evidence-based psychotherapy and skill-building.
A K-hole is an informal term describing an intense ketamine-related dissociative state.
Someone may experience profound detachment from the body, distorted perception of time or space, hallucinations, confusion, difficulty moving or communicating, and memory impairment.
The term is sometimes used casually in recreational-drug culture.
Severe dissociation should not be confused with the controlled effects anticipated during legitimate medical treatment.
Ketamine has also been used or investigated for certain chronic pain conditions.
Its activity at NMDA receptors may influence how the nervous system processes pain.
However, chronic pain can involve much more than one pathway.
Pain may interact with depression, anxiety, trauma, sleep disturbance, deconditioning, injury, stress, medication use, and substance use.
Temporary pain reduction does not necessarily mean a person’s mobility, sleep, function, or quality of life improves over the long term.
For many people, chronic pain care works best when several treatment strategies are considered together.
One of the best-documented physical complications associated with repeated heavy ketamine misuse is ketamine-induced cystitis.
This condition can cause substantial inflammation and urinary-tract damage.
Symptoms may include frequent urination, urinary urgency, painful urination, pelvic pain, blood in the urine, and reduced bladder capacity.
A 2024 published case report described a 46-year-old man with approximately seven months of daily recreational ketamine use who developed significant urinary abnormalities and ketamine-induced cystitis.
Someone experiencing urinary symptoms while frequently using ketamine should receive medical evaluation.
K-cramps is an informal term used for severe abdominal pain reported by some people with chronic ketamine use.
Abdominal pain has many possible causes, so someone should not assume ketamine is responsible without medical evaluation.
However, chronic ketamine misuse has been associated with gastrointestinal dysfunction and severe abdominal symptoms.
Persistent or severe abdominal pain warrants medical attention.
Repeated exposure can change how someone responds to ketamine.
A person may find that the effects become less intense or that they begin seeking larger or more frequent amounts.
Tolerance alone is not the same as addiction.
But escalating doses, increasing frequency, cravings, and difficulty controlling use are important warning signs.
There is not one universally established ketamine withdrawal syndrome that occurs in every person.
Some people with heavy or compulsive use report cravings, low mood, anxiety, irritability, restlessness, or sleep problems after stopping.
Another challenge is determining whether symptoms reflect ketamine cessation or the return of an underlying condition such as depression, trauma, anxiety, or chronic pain.
Evidence regarding medical treatment of ketamine use disorder remains limited, which makes individualized behavioral-health assessment especially important.
No.
Spravato is administered through a specific FDA-required healthcare framework.
Patients receive treatment in certified healthcare settings and remain under observation afterward.
At-home ketamine programs may involve compounded ketamine or other products.
The prescribing process, patient screening, pharmacy oversight, follow-up, and emergency procedures can vary.
The FDA’s June 2026 enforcement activity is an important reminder that consumers should not assume every website selling ketamine products is operating within appropriate medical or regulatory safeguards.
Ketamine-derived treatment is only one possible approach to depression.
CBT helps people understand the relationship between thoughts, emotions, and actions.
It can be used to address depressive thinking, avoidance, unhealthy coping patterns, substance-use triggers, and relapse risk.
Green Springs Wellness provides cognitive behavioral therapy in New Jersey.
Depression frequently leads people to withdraw from routines, relationships, and activities that once provided meaning.
Behavioral activation helps gradually rebuild healthy structure, participation, and reinforcement.
When depression is closely connected to trauma, treating only depressive symptoms may not be enough.
Trauma-focused treatment can help patients process traumatic experiences and develop healthier responses to triggers.
Group treatment can reduce isolation, reinforce coping skills, and provide opportunities to practice new behaviors in a supportive setting.
Traditional antidepressants and other psychiatric medications may remain appropriate depending on the person’s diagnosis, symptoms, treatment history, and medical needs.
Not everyone struggling with depression, addiction, or co-occurring conditions needs residential treatment.
Some people need more structure than weekly therapy but can continue living safely at home.
Green Springs Wellness offers several levels of structured behavioral-health care in Hillsborough, New Jersey.
A Partial Hospitalization Program provides substantial daytime structure without requiring a person to remain at the facility overnight.
PHP may be appropriate when symptoms require more support than standard outpatient therapy but inpatient or residential treatment is not clinically necessary.
Green Springs Wellness’ Intensive Outpatient Program combines individual therapy, group therapy, skill-building, CBT, DBT, and trauma-informed care while allowing clients to maintain greater connection with home, work, school, and family responsibilities.
The Outpatient Program provides ongoing treatment for people who are stable enough to live independently while continuing therapy, medication management when appropriate, relapse prevention, and recovery work.
The appropriate level of care depends on symptom severity, safety, substance use, home support, and everyday functioning.
Ask whether treatment involves FDA-approved Spravato, ketamine used off-label, or a compounded ketamine product.
Both can occur legitimately, but patients should understand which applies to their treatment.
Ask who performs the medical and psychiatric evaluation, monitors blood pressure and other side effects, evaluates treatment response, and manages complications.
People with current or previous substance misuse should understand how cravings, dose escalation, drug-seeking behavior, or increasing interest in dissociation will be addressed.
Ask whether psychotherapy, behavioral treatment, psychiatric medication management, trauma treatment, rehabilitation, or other interventions are being used alongside medication.
A treatment plan should address what happens after initial symptom improvement rather than focusing exclusively on repeated doses.
Professional assessment may be appropriate when someone begins increasing ketamine use, using larger amounts, obtaining ketamine outside legitimate medical care, hiding use, seeking intoxication or dissociation, developing strong cravings, continuing despite urinary or abdominal problems, combining ketamine with other substances, or feeling unable to cope emotionally without it.
A person does not need to wait until severe addiction develops before asking for help.
It is important to avoid stigmatizing people receiving legitimate psychiatric treatment.
Spravato has an FDA-approved role for specific depressive conditions.
A person receiving appropriately supervised esketamine should not automatically be labeled as having a substance problem.
At the same time, medications with psychoactive and reinforcing effects require appropriate screening and monitoring.
A medication can provide meaningful benefit while still carrying meaningful risks.
When depression occurs alongside addiction, addressing only one side of the problem can leave important symptoms and relapse drivers unresolved.
Green Springs Wellness treats depression, trauma, addiction, and other mental health concerns through integrated behavioral-health care in Hillsborough, New Jersey.
Treatment may include CBT, trauma-informed therapy, individual counseling, group therapy, relapse prevention, medication management, PHP, IOP, or outpatient care.
The appropriate plan depends on the person’s symptoms, safety, substance-use history, home environment, and ability to function day to day.
No. Spravato contains esketamine, which is chemically related to ketamine. Spravato has specific FDA-approved depression indications and is administered through a restricted healthcare program.
Ketamine itself is FDA-approved as an anesthetic rather than specifically for psychiatric disorders. Ketamine may be used off-label for depression in some clinical settings.
For treatment-resistant depression, current FDA labeling allows Spravato to be used as monotherapy or together with an oral antidepressant. For depressive symptoms associated with major depressive disorder and acute suicidal ideation or behavior, it is used together with an oral antidepressant.
Spravato can cause sedation, dissociation, respiratory depression, and blood-pressure changes. Its REMS requires administration in certified healthcare settings and post-dose monitoring for at least two hours.
Spravato carries warnings involving abuse and misuse. That does not mean everyone receiving treatment develops addiction, but risk assessment and monitoring are important.
Ketamine has abuse and dependence potential. Risk becomes more concerning when use escalates, occurs outside medical supervision, becomes focused on dissociation, or continues despite negative consequences.
A K-hole is an informal term for an intense ketamine-related dissociative state involving profound detachment, altered perception, confusion, and impaired movement or communication.
Yes. Chronic heavy ketamine use has been associated with ketamine-induced cystitis and other urinary complications.
K-cramps is an informal term describing severe abdominal discomfort reported by some people with chronic ketamine misuse.
There is not one universally defined ketamine withdrawal syndrome. Some people with heavy or compulsive use report cravings, anxiety, low mood, irritability, restlessness, or sleep problems after stopping.
No. Spravato is administered in certified healthcare settings through REMS requirements. At-home ketamine generally involves different products and regulatory circumstances.
Depending on the person, options may include CBT, behavioral activation, trauma-informed therapy, group therapy, antidepressant medication, PHP, IOP, and outpatient behavioral-health care.
Yes. Green Springs Wellness provides structured depression treatment in New Jersey for people experiencing depression, substance-use concerns, and co-occurring behavioral-health conditions.
The appropriate level of care depends on symptom severity, safety, daily functioning, home support, substance use, and previous treatment. Green Springs Wellness offers PHP, IOP, and outpatient treatment in Hillsborough, New Jersey.
The growing interest in ketamine reflects a real need for better ways to treat depression and chronic emotional distress.
Spravato may be appropriate for some patients, and ketamine may have legitimate off-label medical uses.
At the same time, uncontrolled ketamine use can contribute to dependence, dissociation, urinary injury, gastrointestinal problems, and other complications.
For people whose depression, trauma, or anxiety occurs alongside substance use, integrated behavioral-health treatment can address more than one symptom at a time.
Green Springs Wellness provides structured behavioral-health and addiction treatment in Hillsborough, New Jersey through PHP, IOP, outpatient care, CBT, trauma-informed therapy, and co-occurring mental health support.
If you are concerned about ketamine, another substance, or worsening depression, the admissions team can help explain available treatment options and determine which level of care may be appropriate.
You can also complete a confidential insurance verification.
Green Springs Wellness is located at 390 Amwell Rd, Building 5, Suite 504, Hillsborough, NJ 08844. Call (732) 963-4836 to speak with the admissions team.
Quality, Safety and Community Trust
Green Springs Wellness is committed to responsible, transparent and evidence-based behavioral healthcare. These credentials reflect our dedication to patient safety, privacy, ethical operations and quality care.
The Gold Seal of Approval® recognizes Green Springs Wellness’s adherence to rigorous national standards for healthcare quality, patient safety and continuous performance improvement.
LegitScript certification demonstrates that our marketing and operations meet recognized standards for legal compliance, ethical practices, transparency and responsible communication.
Green Springs Wellness operates in accordance with applicable requirements established by the New Jersey Division of Mental Health and Addiction Services.
We protect patient privacy and safeguard protected health information in accordance with federal HIPAA privacy and security requirements.
Positive patient and family feedback reflects our ongoing commitment to compassionate service, clear communication and a supportive treatment experience.
Accreditations, certifications, licenses and recognition may be subject to renewal or change. Contact Green Springs Wellness for current credential and program information.